Evidence map›Paper›PMID 31124077›Full record

ReviewMolecular neurobiology2019

Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization.

Kenneth Blum, M C Gondré-Lewis, E J Modestino, L Lott, D Baron, D Siwicki, T McLaughlin, A Howeedy, M H Krengel, M Oscar-Berman and 6 more

Open access · greenAbstract readReview
In one paragraph

Review in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Dopamine modulation of basolateral amygdala activity and function.Journal of computational neuroscience · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. [Comorbidity of posttraumatic stress disorder and addiction from a biopsychosocial perspective].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 3 countries.

Kenneth BlumGraduate School of Biomedical Sciences, Western University Health Sciences, Pomona, CA, USA. drd2gene@gmail.com.ORCID http://orcid.org/0000-0001-6727-803X
M C Gondré-LewisDepartment of Anatomy, Developmental Neuropsychopharmacology Laboratory, Howard University College of Medicine, Washington, DC, USA.
E J ModestinoDepartment of Psychology, Curry College, Milton, MA, USA.
L LottDepartment of Precision Behavioral Management, Geneus Health, San Antonio, TX, USA.
D BaronGraduate School of Biomedical Sciences, Western University Health Sciences, Pomona, CA, USA.
D SiwickiDepartment of Precision Behavioral Management, Geneus Health, San Antonio, TX, USA.
T McLaughlinCenter for Psychiatric Medicine, Lawrence, MA, USA.
A HoweedyDivision of Neurogenetic Research & Addiction Therapy, The Florida House Experience, Deerfield Beach, FL, USA.
M H KrengelDepartment of Neurology, Boston University School of Medicine and VA Boston Healthcare System, Boston, MA, USA.
M Oscar-BermanDepartment of Neurology, Boston University School of Medicine and VA Boston Healthcare System, Boston, MA, USA.
P K ThanosBehavioral Neuropharmacology & Neuroimaging Laboratory on Addiction, Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA.
I ElmanDepartment of Psychiatry, Cooper University School of Medicine, Camden, NJ, USA.
M HauserDivision of Addiction Services, Dominion Diagnostics, North Kingston, RI, USA.
L FriedDepartment of Precision Behavioral Management, Geneus Health, San Antonio, TX, USA.
A BowirratDivision of Anatomy, Biochemistry and Genetics Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
R D BadgaiyanDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Christus Health · USBoston University · USAn-Najah National University · PSCooper University Hospital · USCurry College · USDominion Diagnostics (United States) · USEötvös Loránd University · HUHoward University · USIcahn School of Medicine at Mount Sinai · USUniversity at Buffalo, State University of New York · USWestern University of Health Sciences · US

Funding

Research_ProjectU54HD090257 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI GIOIA, GERARD A. · 2016 to 2020
$5.9M
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
$221k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479National Institute for Health Research G12MD007595/National Institute for Health Research R01HD70888NICHD NIH HHS U54 HD090257NIMHD NIH HHS R41 MD012318University New York Research Foundation Q0942016
6 · The paper itself

Abstract

Post-traumatic stress disorder (PTSD) is a severe polygenic disorder triggered by environmental factors. Many polymorphic genes, particularly the genetic determinants of hypodopaminergia (low dopamine function), associate with a predisposition to PTSD as well as substance use disorder. Support from the National Institutes of Health for neuroimaging research and molecular, genetic applied technologies has improved understanding of brain reward circuitry functions that have inspired the development of new innovative approaches to their early diagnosis and treatment of some PTSD symptomatology and addiction. This review presents psychosocial and genetic evidence that vulnerability or resilience to PTSD can theoretically be impacted by dopamine regulation. From a neuroscience perspective, dopamine is widely accepted as a major neurotransmitter. Questions about how to modulate dopamine clinically in order to treat and prevent PTSD and other types of reward deficiency disorders remain. Identification of genetic variations associated with the relevant genotype-phenotype relationships can be characterized using the Genetic Addiction Risk Score (GARS®) and psychosocial tools. Development of an advanced genetic panel is under study and will be based on a new array of genes linked to PTSD. However, for now, the recommendation is that enlistees for military duty be given the opportunity to voluntarily pre-test for risk of PTSD with GARS, before exposure to environmental triggers or upon return from deployment as part of PTSD management. Dopamine homeostasis may be achieved via customization of neuronutrient supplementation "Precision Behavioral Management" (PBM™) based on GARS test values and other pro-dopamine regulation interventions like exercise, mindfulness, biosensor tracking, and meditation.

Indexed as

BehaviorSocial StigmaDopamineHumansStress Disorders, Post-TraumaticDopamineGenetic addiction risk score (GARS™)HypodopaminergiaNeuronutrientPost-traumatic stress disorder (PTSD)Pro-dopamine regulation (KB220PAM)

Identifiers

PMID31124077
PMCPMC6815696
OpenAlexW2945778644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.